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Increased recognition of parvovirus B19 (B19), an erythrovirus, as a significant human pathogen that
causes fetal loss and severe disease in immunocompromised patients has resulted in intensive
efforts to understand the pathogenesis of B19-related disease, to improve diagnostic strategy that is
deployed to detect B19 infection and blood-product contamination and, finally, to elucidate the
nature of the cellular immune response that is elicited by the virus in diverse patient cohorts. It is
becoming clear that at least three related erythrovirus strains (B19, A6/K71 and V9) are circulating in
the general population and that viral entry into target cells is mediated by an expanding range of
cellular receptors, including P antigen and -integrins. Persistent infection by B19 is emerging as a
contributory factor in autoimmune disease, a hypothesis that is constrained by the detection of B19
in the skin of apparently healthy individuals. B19 infection during pregnancy may account for
thousands of incidences of fetal loss per annum in Europe, North America and beyond, yet there is
currently only minimal screening of pregnant women to assess serological status, and thereby risk of
infection, upon becoming pregnant. Whilst major advances in diagnosis of B19 infection have taken
place, including standardization of serological and DNA-based detection methodologies, blood
donations that are targeted at high-risk groups are only beginning to be screened for B19 IgG and
DNA as a means of minimizing exposure of at-risk patients to the virus. It is now firmly established that
a Th1-mediated cellular immune response is mounted in immunocompetent individuals, a finding
that should contribute to the development of an effective vaccine to prevent B19 infection in
selected high-risk groups, including sickle-cell anaemics.
Parvovirus B19
In 1975, Yvonne Cossart discovered what was to become
known as human parvovirus B19 (B19) (Cossart et al., 1975).
B19 was first associated with disease in 1981, when it was
linked to an aplastic crisis in a patient with sickle-cell disease.
It has since been shown to cause erythema infectiosum (EI)
(fifth disease of childhood), spontaneous abortion and some
forms of acute arthritis (Anderson et al., 1983; Kinney et al.,
1988; Woolf & Cohen, 1995).
B19 is a small, non-enveloped, ssDNA virus and, like all
parvoviruses, the capsid proteins are arranged with icosahe-
dral symmetry. B19 is 20–25 nm in diameter and has a
genome of 5.6 kb (Clewley, 1984; Cotmore & Tattersall,
1984). The B19 capsid consists of an 83 kDaminor structural
protein, VP1, and a 5 kDa major structural protein, VP2.
VP2 makes up about 95% of the total capsid, with VP1
accounting for the remaining 5% (Ozawa et al., 1987). The
sequences of the two proteins are collinear, with VP2 being
identical to the carboxyl-terminus of VP1; however, VP1
comprises an additional 227 aa domain that is unique to the
amino-terminal (Fig. 1). To the left of these sequences on the
B19 genome is the ORF for a non-structural protein, NS1,
which encodes a protein product of 77 kDa. NS1 is a
phosphoprotein with important regulatory functions, in-
cluding control of transcription (Momoeda et al., 1994a) and
virus replication; it also plays a role in host-cell death (Ozawa
et al., 1988). It possesses DNA-binding properties (Raab
et al., 2002) and biochemical activities, such as ATPase,
helicase and site-specific endonuclease activities, as well as
nuclear localization signals (Li&Rhode, 1990;McCarty et al.,
1992; Jindal et al., 1994; Brown & Young, 1997). B19 NS1 has
also been shown to affect G1, but not G2, arrest in erythroid
UT7/Epo-S1 cells (Morita et al., 2003). B19 uses a single
promoter, p6, which is capable of expressing structural and
non-structural genes differentially (Blundell et al., 1987;
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Ozawa et al., 1987). It has been demonstrated that NS1
interacts directly with the p6 promoter and with cellular
transcription factors Sp1/Sp3 to affect transcriptional reg-
ulation (Raab et al., 2002). Two other small polypeptides
have been identified, one encoded by a region in the middle
of the genome with a predictedMr of 7.5 kDa and the other,
which is encoded at the extreme right-hand end of the
genome, with a predicted Mr of 11 kDa (St Amand et al.,
1991). Spliced transcripts of these two polypeptides have
been found in infected cells, but their function has been
hitherto unknown (Luo & Astell, 1993).
As a result of increased awareness of and screening for B19, a
number of novel genotypes have been identified. Servant
et al. (2002) suggested that B19 should be classified as a
genotype 1 erythrovirus, with newly identified strains A6
(Nguyen et al., 2002) and K71 (Hokynar et al., 2002)
classified as genotype 2 and erythrovirus V9 (Nguyen et al.,
1998) as the prototype of genotype 3. V9 has overall
nucleotide sequence variation of about 12% from B19
isolates, with the majority of sequence divergence occurring
in the 59 portion of the VP1 unique region; however,
differences in sequence are not restricted to this area, but
are scattered throughout the genome (Nguyen et al., 1999;
Heegaard et al., 2001). K71 persists in human skin and has a
nucleotide divergence of 10.8% fromB19 and 8.6% fromV9
(Hokynar et al., 2002).
Infectivity, transmission and epidemiology
The only known host for B19 is humans. The virus replicates
in human erythroid progenitor cells (late erythroid cell
precursors and burst-forming erythroid progenitors) of
the bone marrow and blood, inhibiting erythropoiesis
(Mortimer et al., 1983). Tropism of productive B19 infection
is mainly due to the restrictive cellular distribution of the P
blood group antigen globoside (Gb4) (Brown et al., 1993,
1994), which is found most commonly on cells of the
erythroid lineage, but also on platelets, tissues from the
heart, liver, lung, kidney and endothelium and on synovium
(Cooling et al., 1995; Jordan & DeLoia, 1999). Individuals
who lack erythrocyte P antigens are very rare (1 in 200 000)
and apparently cannot be infected by B19 (Brown et al., 1994;
Chipman et al., 1996).
The limited tropism of B19 is not fully understood, as
reduced capsid expression has been observed in non-
permissive cells; however, intracellular factors that are found
only in erythroid cells are assumed to be essential for optimal
transcription and virus replication (Ozawa et al., 1987;
Kurpad et al., 1999; Gallinella et al., 2000). It has been shown
that the level of P antigen expression on cells is not related
directly to the efficiency of virus binding. In addition, some
cell lines cannot be transduced by a B19 vector, despite P
antigen expression and virus binding to the P antigen, thus
indicating that a co-receptor is probably essential for virus
entry into human cells (Weigel-Kelley et al., 2001). Thus,
recent evidence suggests that the presence of the P antigen
alone is not sufficient to gain entry into cells (Weigel-Kelley
et al., 2001) and it has been suggested that multiple -
integrins may function as co-receptors for B19 cellular
assimilation (Weigel-Kelley et al., 2003).
B19 studies have been hampered by difficulties in propagat-
ing the virus in vitro. Recent studies have indicated that
infection under hypoxic conditions [1% (v/v) O2] causes
upregulation of B19 expression, which is associated with
increased virus replication and production of infectious
virions (Pillet et al., 2002). Due to the cytotoxic nature of
the non-structural protein NS1, no continuous cell line that
propagates B19 has been established (Ozawa et al., 1987;
Momoeda et al., 1994b).
B19 transmission occurs most commonly by personal con-
tact via aerosol or respiratory secretions; however, contami-
nated blood products, such as clotting factor concentrates,
are a source of iatrogenic transmission (Anderson et al., 1985;
Lyon et al., 1989; Williams et al., 1990; Santagostino et al.,
1994; Erdman et al., 1997). B19 can be transmitted trans-
placentally from an infected mother to her fetus, which may
lead to non-immune fetal hydrops (NIHF), spontaneous
abortion or intrauterine fetal death (IUFD) (Clewley et al.,
1987; Miller et al., 1998; Skjoldebrand-Sparre et al., 2000).
The P blood group antigen, which serves as a receptor for
B19, has been detected on cells of the villous trophoblast of
placental tissues in varying amounts during the course of
pregnancy. In the first trimester, levels of the P antigen are
very high; they begin to decline in the second trimester and
become undetectable by the mid-stages of trimester 3
(Jordan & DeLoia, 1999). This high level of globoside
receptor on placental cells in early pregnancy may act as a
pathway for B19 to be transmitted from the mother to the
fetus, whereby the virus can then infect erythroid progenitor
cells for replication. In support of this hypothesis, Wegner &
Jordan (2002) have shown conclusively that 125I-labelledVP2
capsid interaction with villous cytotrophoblast cells is
mediated by P antigen.
Infection with B19 is very common and cases of infection
have been reported all over the world in all seasons.
Seroprevalence increases with age and, by adulthood,
Fig. 1. Schematic representation of human parvovirus B19 genome
and transcription map [redrawn with permission from Gray et al.
(1998)].
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.70% of the adult population is seropositive (Kerr et al.,
1999). Children are the main source of transmission and
outbreaks can persist for months in schools and day-care
centres, due to the relatively large number of seronegative
children and close contact of children within this environ-
ment (Tuckerman et al., 1986; Grilli et al., 1989). The annual
seroconversion rate among women of childbearing age has
been estimated to be 1.5% during endemic periods and 13%
during epidemics (Koch & Adler, 1989; Valeur-Jensen et al.,
1999). Furthermore, infection by B19 during pregnancy can
lead to spontaneous abortion or fetal anaemia. Conse-
quently, the question must now be posed whether the
B19 immune status of pregnant women should be deter-
mined routinely on initial presentation, to facilitate im-
proved pregnancy outcome with respect to potential B19
infection.
Manifestations and clinical symptoms
B19 has been associated with an expanding range of clinical
disorders since the discovery that it is the aetiological agent of
EI. This is a mild childhood illness that is characterized by an
erythematous rash that affects the face, trunk and limbs of the
body. It is also associated with complications during preg-
nancy, acute arthropathy, disease in immunocompromised
patients and transient aplastic crisis (TAC).
B19 infection and pregnancy
Exposure to and infection by B19 can lead to serious
complications during pregnancy. Infection during preg-
nancy may result in fetal anaemia, spontaneous abortion
and hydrops fetalis (Brown et al., 1984; Kinney et al., 1988;
Heegaard & Hornsleth, 1995). About 30–40% of women
are non-immune and do not possess neutralizing antibodies
to B19 and, therefore, are susceptible to infection by this
virus. A vertical transmission rate of 33% has been reported
by the Public Health Laboratory Service in the UK (PHLS,
1990) and others have reported similar rates (Brown et al.,
1984; Hall et al., 1990), although a recent study reported
a transmission rate of 51% (Yaegashi, 2000). There are
over four million births in Europe per annum (Eurostat,
1998) and, because 30% of pregnant women are B19-
seronegative, over 1 200 000 European women are therefore
susceptible to B19 infection during pregnancy. Assuming a
combined rate of infection and fetal loss of 0.2% (Levy
et al., 1997; Miller et al., 1998; Wattre et al., 1998), it can be
estimated that approximately 3000 pregnancies per annum
may be lost. Analogous birth rates in the USA and Canada
imply that a similar incidence of fetal death due to B19
infection can be expected for these countries. These
calculations are based solely on live births and, as the
number of actual pregnancies is much higher, the above
estimate is conservative. Pregnant women are most suscep-
tible to B19 infection during epidemics and also when
exposed to infected children in the home (Valeur-Jensen
et al., 1999). During outbreaks, transmission rates of 25%
in schools and 50% at home have been reported (Anderson
et al., 1990). Most pregnant women are asymptomatic, but
some do experience symptoms, such as exanthema and
arthralgia (Komischke et al., 1997). As these symptoms are
commonly associated with pregnancy, acute B19 infection
can often be overlooked; however, routine screening for
symptoms of B19 infection or seroconversion would over-
come this problem.
Fetal death usually occurs 4–6 weeks post-infection, but has
been reported up to 12 weeks after B19 symptomatic
infection (Hedrick, 1996). A study of 427 pregnant women
with B19 infection in the UK observed that fetal loss was
confined to the first 20weeks of gestation (Miller et al., 1998).
This is supported by figures released in the UK and other
studies, which reported that fetal loss as a consequence of
intrauterine B19 infection is highest in, but not restricted to,
the first 20 weeks of gestation (Hall et al., 1990; PHLS, 1990).
The critical time of infection has since been narrowed down
to the 16th week of gestation (Yaegashi et al., 1999). Most
cases of fetal loss due to B19 infection have been reported in
the second trimester (Enders & Biber, 1990; Torok, 1990;
Wattre et al., 1998). This susceptibility could be attributed, at
least in part, to the relative immaturity of the fetal immune
response at this stage. More important, though, is the
tropism that B19 has for erythroid progenitor cells
(Yaegashi, 2000) and the fact that in the second trimester
of pregnancy, the life-span of fetal red blood cells (RBCs)
is shortened and RBC mass increases three- to fourfold
during this period of gestation (Rodis et al., 1988). B19
replication within erythroid progenitor cells leads to apop-
tosis, which ultimately results in inhibition of erythropoiesis
(Morey et al., 1993). Erythroblastopenia can then occur
as a consequence of B19 replication, causing severe fetal
anaemia.
Anaemia is an underlying factor in the development of
hydrops. Fetal hydrops was first associated with B19 in 1984
(Brown et al., 1984). Since then, 10–20%of NIHF cases have
been reported to be B19-associated (Yaegashi et al., 1994;
Jordan, 1996) and, in a study of B19 infection in Japanese
women during pregnancy, the risk of hydrops was deter-
mined to be about 10% (Yaegashi et al., 1999). NIHF usually
occurs 2–4 weeks after maternal B19 infection (Komischke
et al., 1997). Cases of IUFD that are associated with fetal
hydrops and caused by B19 have been reported most
commonly in the second trimester and, to a lesser extent
(unquantified as yet), in the third trimester of pregnancy
(Sanghi et al., 1997). When cases of IUFD that occurred
during an 18 month period in the UK were examined, it was
discovered that 11 deaths were caused by B19 in the second
trimester and, of these, only three were hydropic (Wright
et al., 1996). In a separate study over a 16 year period, ten
cases of IUFD were reported, which presented in gestational
weeks 15–29. Of those cases, 90% of the fetuses were
hydropic, 30–40% had associated heart failure and three
of the maternal infections were asymptomatic (Morey et al.,
1993).
Until recently, third-trimester fetal loss or IUFD caused by
acute B19 infection had not been widely reported. However,
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of 93 IUFD cases that were examined, 7.5% had B19 DNA
in placental tissue in the absence of fetal hydrops
(Skjoldebrand-Sparre et al., 2000). Unusually, none of the
infected pregnant women in this study showed any clinical
symptoms of B19 infection. B19-associated IUFD in the final
stages of gestationmay have been overlooked previously, due
to inadequate diagnostic procedures and the difference in
clinical features of third-trimester B19 infection. The most
striking observation in these IUFD cases was the lack of fetal
hydrops and the fact thatmany of the cases had either delayed
or absent B19 IgG responses. Histopathological examination
of the fetuses revealed no major abnormalities. Similar
reports of non-hydropic, third-trimester IUFD that was
associated with B19 infection have been published
(Tolfvenstam et al., 2001a). Here, it was revealed by PCR
analysis of fetal or placental tissues that 15% of IUFD cases
were attributable to B19 infection. This study also observed
delayed B19-specific antibody responses, as the mothers
involved had no serological evidence of an acute B19
infection. However, follow-up studies showed evidence of
seroconversion within 6 months. Tissue samples showed no
signs of virus inclusions and immunochemistry analysis
revealed no evidence of B19 proteins (Tolfvenstam et al.,
2001a). Although the concept of B19-induced, third-
trimester fetal loss has proved somewhat controversial
(Crowley et al., 2001; Sebire, 2001), it further illustrates the
requirements for awareness of B19 pathogenesis and diag-
nostic B19 PCR screening during pregnancy. Furthermore,
Nunoue et al. (2002) suggested strongly that prospective
studies to evaluate the relationship between time of infection
and IUFD, with and without signs of fetal hydrops, are
necessary. In fact, B19 PCR may be the most sensitive way
of diagnosing intrauterine B19 infection, especially as
.50% of infected fetuses test negative for B19 IgM (Dieck
et al., 1999).
Administration of high-titre intravenous immunoglobulin
(IVIG) has been shown to be successful in treating fetal
hydrops in some cases (Selbing et al., 1995; Alger, 1997). For
cases of fetal infection, intrauterine blood transfusions may
be beneficial (Schwarz et al., 1988a; Hansmann et al., 1989),
especially in the case of hydrops, but this procedure does
involve additional risks to the outcome of pregnancy (Berry
et al., 1992; Cameron et al., 1997; Bousquet et al., 2000). A
study by Wattre et al. (1998) reported two cases where
intrauterine blood transfusions led to the cessation of
symptoms and the birth of normal babies. In a separate
study, 38 cases of B19-associated fetal hydropswere reported,
12 of which received intrauterine blood transfusion.
Although three of these fetuses subsequently died, the
probability of death among fetuses that did not receive a
blood transfusion was significantly higher (Fairley et al.,
1995). In addition, spontaneous resolution of hydrops
without intervention has been reported, suggesting that
treatment is not always necessary (Pryde et al., 1992).
B19 infection during pregnancy is not a significant cause of
birth defects; however, at least one incidence of congenital
cardiomyopathy has been linked to B19 infection (Barton
et al., 1997).
Arthropathy
Like the rubella virus (Lee, 1960), B19 infection has also been
linked to arthritis and arthralgias, most commonly in adults,
but also in children (Reid et al., 1985). On average, 50% of
adult cases of EI have associated joint manifestations that
may persist for up to 1 month (Cassinotti et al., 1995). B19
arthritis is usually symmetrical, affecting mainly the small
joints of the hands, wrists and knees (Reid et al., 1985). It is
more common in females thanmales, with an estimated 60%
of women with symptomatic disease that manifests in
arthropathy (White et al., 1985; Woolf et al., 1989). Symp-
toms generally subsidewithin 3weekswithout any damage to
the joints (Woolf et al., 1991), but about 20% of affected
women suffer persistent or recurring arthropathy. About
75% of these patients have an associated rash and ,20%
have the typical ‘slapped cheeks’ facial exanthem. B19 has
been proposed as the causative agent of arthritic conditions
that exhibit similar symptomologies to those found in
rheumatoid arthritis (RA), juvenile RA and erosive poly-
arthritis, as recent B19 infection and high levels of B19
antibodies have been evident in many of these patients
(White et al., 1985; Nocton et al., 1993; Mimori et al., 1994;
Tyndall et al., 1994). It has been suggested that B19-
associated arthritis is related to certain human leukocyte
antigen (HLA) haplotypes of patients, with individuals of
eitherHLADR4 or B27 beingmost susceptible (Klouda et al.,
1986; Jawad, 1993); however, it is unclear how B19 causes
symptoms that are associatedwith arthritis. Analogous to the
appearance of exanthema in EI, arthritis usually occurs after
development of B19-specific antibodies. This suggests that
symptoms may be due to formation of immune complexes.
Despite the fact that the P antigen is expressed on synovium,
it has been shown that synovial membrane cells are non-
permissive to B19 (Miki & Chantler, 1992; Cooling et al.,
1995). Normal human synovial fibroblasts have been shown
to exhibit increased invasiveness following exposure to B19
viraemic serum, as judged by the acquired ability to degrade
reconstituted cartilage matrix (Ray et al., 2001). B19 may
gain entry to cells that possess the B19 receptor but are not
actively dividing, resulting in the production of excessive
cytotoxic NS1 (Ozawa et al., 1988). The B19 NS1 protein
causes the secretion of proinflammatory cytokines, which
could cause the inflammation and cell damage that are seen
in patients with B19-associated arthritis and other inflam-
matory and autoimmune disorders that have been linked to
B19 infections (Moffatt et al., 1996; Mitchell, 2002). In one
study, antibodies that were specific for the non-structural
protein NS1 were found in patients with persistent B19-
associated arthropathy, but not in serum from individuals
with evidence of past infection without complications (von
Poblotzki et al., 1995a), thus suggesting an altered host
response in the former cohort. However, others have
disputed this, reporting similar NS1 antibody reactivity in
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patients with chronic or acute B19-associated arthropathy
(Mitchell et al., 2001) and recently infected healthy indivi-
duals (Searle et al., 1998; Ennis et al., 2001; Mitchell et al.,
2001; Heegaard et al., 2002a). von Landenberg et al. (2003)
further suggested that B19 may be involved directly in the
induction of autoimmune reactions that are mediated, at
least in part, by anti-phospholipid antibodies, because of the
prevalence of these antibodies in persistently B19-infected
individuals.
There is significant evidence of B19 DNA persistence in bone
marrow, peripheral blood and synovial tissues of patients
with chronic, B19-associated arthropathy (Foto et al., 1993;
Musiani et al., 1995; Nikkari et al., 1995). However, it has
also been shown that although B19 DNA persisted in the
synovium tissue of 28% of children who presented with
chronic arthritis, an even higher proportion (48%) of
seropositive, immunocompetent volunteers had B19 DNA
in their synovium tissues. These results imply that B19 DNA
in synovium tissue may not be associated directly with
symptoms of chronic arthropathy. None of the individuals
tested had evidence of B19 DNA in their synovial fluid, bone
marrow or blood and all were positive for B19 IgG antibodies
(So¨derlund et al., 1997). Nonetheless, a recent report further
enhanced the correlation between B19 infection and rheu-
matic childhood disease (Lehmann et al., 2003). This work
clearly elucidated a significant difference in serum and/or
synovial fluid-derived B19 DNA (P , 0.0001) between
control (9/124, 7%) and patient (26/74, 35%) specimens
and concluded that the rate of persistent B19 infection in
these patients is significantly higher than in age-matched
controls.
The recent finding of B19 DNA in 64% (14/22) of control
skin biopsies, compared to 50% (18/36) of chronic urticaria
patients, confirms that caution should be exercised in
drawing conclusions regarding B19 involvement in skin
disorders and possibly in other B19-associated clinical
disorders (Vuorinen et al., 2002).
Chronic B19 infection in the immunocompromised host
A host with a compromised immune system is particularly
at risk of B19 infection, including people with AIDS, cancer
patients who are receiving chemotherapy and transplant
patients on immunosuppressive drugs (Young, 1996). Many
are unable to produce neutralizing antibodies to clear the
virus and this can lead to persistent infection, resulting in
anaemia (Kurtzman et al., 1989a; Young, 1996). In one case
study, an AIDS patient developed severe anaemia as a result
of chronic pure red-cell aplasia that was caused by B19
infection (Koduri et al., 1997). Despite remission following
IVIG transfusions, the patient suffered several recurrences
of severe anaemia. In another report, sera obtained from
transplant patients who were receiving bone-marrow grafts
(n ¼ 27) were analysed by PCR (Schleuning et al., 1999). Of
the cohort tested, 15% were B19 DNA-positive and many of
these patients also developed a reticular rash. Although
development of a rash during B19 infection is thought to be
mediated by formation of immune complexes, these pa-
tients did not exhibit any signs of a B19-specific antibody
response. Therefore, it was hypothesized that the rash was a
consequence of a direct virus effect on the skin; this finding
is supported by the fact that B19 DNA has been found
previously in a skin biopsy from a male patient with B19-
associated fever, rash and polyarthritis (Nikkari et al., 1996).
Persistant B19 infection results in chronic suppression of
erythropoiesis with chronic anaemia. A report by Graeve
et al. (1989) described how four children who were under-
going cancer chemotherapy treatment were infected by B19,
resulting in chronic bone-marrow suppression. Schleuning
et al. (1999) also reported that one of the transplant patients
subsequently died from heart failure and B19 DNA was
detected in the myocardium, but not in peripheral blood,
indicating that heart failure was a consequence of B19
infection [heart failure has been recognized as a feature of
B19 infection in the past (Chia & Jackson, 1996)]. Another
of the transplant patients investigated was found to have
developed hepatitis (Schleuning et al., 1999), which was also
attributed to B19 infection (Yoto et al., 1996). As these
transplant patients were subjected to strict decontamination
procedures, including isolation in single rooms with posi-
tive airflow and decontaminated food, it is thus unlikely
they contacted B19 via respiratory secretions. Platelet
concentrates were screened for B19 prior to administration
and were therefore not a likely source of transmission.
However, as B19 DNA in clotting and immunoglobulin
concentrates is known to cause infection, this may have
been the route of transmission for the virus (Saldanha &
Minor, 1996).
Many immunocompromised patients with chronic anaemia
respond positively to IVIG therapy; however, individuals
may suffer from recurrent relapses of aplasia (Koduri et al.,
1997, 1999;Moudgil et al., 1997). In addition, administration
of IVIG may not always be effective, as infection may persist
despite treatment, particularly in transplant patients who
are heavily immunosuppressed (Moudgil et al., 1997;
Schleuning et al., 1999; Lui et al., 2001). To date, no data
are available on the actual protective level of B19 IgG,
although levels of .6 IUml1 are thought to be protective
(Searle et al., 1997). As patients fail to mount an antibody
response, serological diagnosis is futile and detection of B19
infection is therefore usually achieved by B19 DNA detection
via a PCR assay.
Transient aplastic crisis (TAC)
B19-associated TAC may occur in individuals who exhibit
underlying chronic haemolytic disorders, such as hereditary
spherocytosis (Beland et al., 1997). In 1981, it was discovered
that B19 caused TAC in children with sickle-cell anaemia
(Serjeant et al., 1981) and it is now clear from subsequent
studies that almost 70% (118/177) of B19 infections in this
cohort resulted in TAC (Serjeant et al., 2001).
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Vaccine
No specific therapy is required for B19 infection in immu-
nocompetent individuals. Symptoms of arthropathy can be
treated with non-steroidal, anti-inflammatory drugs.
Humoral immune response
B19 viraemia occurs 1 week after exposure and usually lasts
about 5 days, with virus titres peaking on the first 2 days. B19-
specific IgM antibodies are detected late in the viraemic stage
(at about day 10 or 12) and can persist for up to 5 months
(Anderson et al., 1985; Schwarz et al., 1988b; Yaegashi et al.,
1989) but, in some patients, can last even longer (Musiani
et al., 1995). Specific IgG antibodies are detectable about 15
days post-infection, remain high for several months and
persist long-term. IgA antibodies are detectable for a short
period following the onset of clinical symptoms (Erdman
et al., 1991). Development of the antibody response corre-
sponds to virus clearance and also, in the vast majority of
cases of B19 infection in immunocompetent individuals,
protection from disease (Anderson et al., 1985). A study of
children with sickle-cell disease showed that those who had
had one episode of B19-associated TAC did not suffer a
second episode (Serjeant et al., 1993).
Historically, the B19 VP1 protein, and in particular the VP1-
unique region, was thought to be the immunodominant
antigen and its incorporation into serological assays was
thought to be essential (Rayment et al., 1990). However, it is
now clear that this observation, which was based on the
absence of antibodies to linear epitopes of VP2 when
screened by Western blot, was somewhat erroneous. It has
now been established conclusively that antibodies against
capsid VP2 are maintained, even when B19 IgG directed
against the VP1-unique region is lost (Kerr et al., 1999;
Manaresi et al., 1999; Corcoran et al., 2000).
Specific anti-virus antibody is considered to be a significant
mechanism of immune protection, based on the circum-
stantial evidence that high-dose immunoglobulin therapy is
sometimes beneficial in infected patients (Kurtzman et al.,
1989b; Schwarz et al., 1990). Antibodies against linear
epitopes of VP2 and, to some extent, VP1 disappear abruptly
after B19 infection, whereas IgG reactivity against conforma-
tional epitopes of both VP1 and VP2 persists (So¨derlund
et al., 1995; Kerr et al., 1999). Persistent infections that are
associatedwith chronic anaemiawhere the immune response
to B19 has failed to produce neutralizing antibodies or they
have been at very low levels have been observed (Kurtzman
et al., 1987, 1988; Coulombel et al., 1989).
Diagnosis of B19 infection – choice of antigen
Accurate laboratory diagnosis of recent B19 infection or past
exposure relies on screening plasma specimens for either
specific antibody reactivity against virus capsid proteins that
are expressed in eukaryotic expression systems (e.g. the
baculovirus expression system) or for B19 DNA by using
PCR. Immunoassays that only incorporate Escherichia coli-
expressed B19 antigens, which have undergone denaturation
as part of the manufacturing process, will produce false-
negative results, due to the absence of conformational
epitopes (Jordan, 2000). A unique advantage of the eukar-
yotic baculovirus expression system is its ability to direct the
post-translational protein folding that is necessary for the
production of soluble, conformationally intact VP2 capsid
proteins (Brown et al., 1990; Kerr et al., 1995a). Unlike B19
VP2, VP1 does not appear to form soluble capsid structures;
however, VP1 has been produced as a ‘conformationally
intact’ protein that retains conformational epitopes that are
present in the native virion (Brown et al., 1990; Kerr et al.,
1999).
A number of authors have stated that co-expression of VP1
and VP2 in eukaryotic expression systems results in the
formation of empty capsids that are antigenically analogous
to native B19 virions. Furthermore, it has been hypothesized
that such co-capsids contain conformational epitopes that
are essential for accurate detection of infection (Kajigaya
et al., 1989, 1991; Franssila et al., 2001; Ballou et al., 2003). To
date, there are no data to prove that co-capsids are actually
present in such preparations and it cannot be excluded that
separate, conformationally intact entities that are comprised
of either VP1 or VP2 are in fact present.
More recent evidence from a number of authors now
suggests that B19 NS1 IgG and IgM detection also plays a
significant role in diagnosis of acute infection, thereby
supplementing the role played by B19 capsid antigens as
diagnostic antigens (Ennis et al., 2001; Heegaard et al.,
2002a).
B19 IgM immunodetection
Acute B19 infections are confirmed by B19-specific IgM
reactivity, whereas past infections are detected by IgG
reactivity (Anderson et al., 1985). In most situations, IgM
antibodies appear 7–10 days post-infection and are directed
against linear and conformational epitopes of VP1 and VP2
(Palmer et al., 1996; Manaresi et al., 2001). It has been
reported that IgM against conformational epitopes on VP1
and VP2 and against linear epitopes on VP1 appears at the
same time post-infection and at the same frequency. How-
ever, it was also revealed that IgM reactivity against theminor
capsid protein, VP1, may persist somewhat longer post-
infection (Palmer et al., 1996; Manaresi et al., 2001). If IgM
responses against conformational VP1 persist when other
B19-specific IgM antibodies are absent, then diagnostic
techniques that incorporate conformational VP1 may not
be the most suitable markers of acute B19 infection. How-
ever, another study observed no difference in IgM reactivity
against conformational epitopes of the capsid proteins in
diagnosing B19 infection (Kerr et al., 1999). Furthermore,
these authors observed no disparity in IgM reactivity against
native (conformationally intact) and linearized antigens for
both VP1 and VP2.
Presently, there is no International Standard preparation for
B19 IgM and only one B19 IgM diagnostic test that has been
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cleared by the US Food and Drug Administration (FDA) is
available. It is am-capture enzyme immunoassay (EIA) that
utilizes B19 recombinant VP2 capsids for the detection of
specific IgM in human serum or plasma. This immunoassay
has 89.1% sensitivity and 99.4% specificity (Doyle et al.,
2000) and is used widely for the diagnosis of recent B19
infection (Jordan, 2000; Mitchell et al., 2001; Vuorinen et al.,
2002). Furthermore, validated alteration of the immuno-
assay cut-off, based on receiver operating characteristic
analysis, facilitates improved immunoassay sensitivity,
which may have a utility in detection of lower levels of
B19-specific IgM in immunocompromised individuals and
young children (Doyle et al., 2000). No evidence of cross-
reactivity with other viral infections, such as rubella, mumps,
varicella-zoster virus, cytomegalovirus, herpes simplex virus-
1 (HSV-1) andHSV-2, is apparentwhen this immunoassay is
used in clinical settings. Previous studies have reported cross-
reactivity with rubella in several commercial B19 IgM assays
(Sloots & Devine, 1996; Tolfvenstam et al., 1996) and as the
symptoms of rubella infection are similar to those of B19
infection, this was a cause for concern, particularly in the
diagnosis of infection in pregnant women. A false-positive
rate of 5% was reported when specimens from healthy
volunteers were analysed with a range of commercially
available B19 IgM immunoassays, probably due to cross-
reactivity and lack of specificity in these immunoassays
(Tolfvenstam et al., 1996).
Detection of B19 NS1 IgM has received little attention as a
marker of recent infection by B19. Ennis et al. (2001)
observed that 27.5% (11/40) of specimens that were B19
VP2 IgM-positive also contained B19 NS1 IgM when tested
by ELISA. Interestingly, when these samples were analysed by
Western blot, there was no evidence of NS1 IgM reactivity,
which indicates that conformational epitopes are important
for detection.
B19 IgG immunodetection
Development of B19 IgG antibodies coincides with a decline
in the IgM response. IgG reactivity against conformational
epitopes of VP1 and VP2 persists post-infection; however,
for both capsid proteins, reactivity against linear epitopes
declines post-infection [abruptly against VP2, but more
slowly against VP1 (So¨derlund et al., 1995; Kaikkonen
et al., 1999; Kerr et al., 1999;Manaresi et al., 1999)]. Antibody
reactivity against linear VP2 epitopes usually disappears
within 6 months of B19 infection (So¨derlund et al., 1995).
This initial reactivity against linearized VP2 appears to be
directed predominantly against a heptapeptide (amino acids
344–350) that was identified by analysis of acute-phase sera
(Kaikkonen et al., 1999).
Although the antibody response wanes against linear epi-
topes on B19 capsid proteins, it persists against confor-
mational epitopes of both capsid proteins. The only
FDA-cleared B19 IgG immunoassay that is available as a
marker of past infection is a microplate immunoassay that
utilizes capsid VP2 to detect B19 and erythrovirus V9 IgG
(Heegaard et al., 2002b; A. Garbarg-Chenon, personal
communication). This baculovirus-based immunoassay
has been compared to another commercially available, E.
coli-based VP1 immunoassay for detection of B19 antibodies
in the sera of pregnant women (Jordan, 2000). A number of
equivocal results were obtained by using the B19 VP1
immunoassay. To verify results, samples were tested by using
a commercially available VP1 immunofluorescent assay
(IFA). This assay examines seroreactivity against conforma-
tionally intact VP1. Although this assay may be somewhat
subjective, as it primarily measures the degree of specimen
fluorescence, when used in parallel with the VP2 IgG
immunoassay, it can confirm B19 reactivity. Results from
the VP1 IFA were similar to those obtained by the baculo-
virusVP2EIA andwere in accordancewith the fact thatmany
of the samples that were found to be equivocal by the E. coli
VP1EIAhad clinical histories of B19 exposure. Availability of
a B19 IgG International Standard (2nd International Stan-
dard 2003; code 01/602; 77 IU per ampoule) should further
assist in accurate confirmation of past B19 infection by
standardizing B19 IgG determination from different labora-
tories that use a variety of test systems (Ferguson et al., 1997;
Searle et al., 1997).
Recently, the importance of antibodies against the B19 non-
structural protein NS1 has been investigated, with a view to
improving diagnosis of B19 infection. The presence of B19
NS1 IgG was thought to be associated primarily with
persistent B19 infection (von Poblotzki et al., 1995a,
1995b); however, several groups have subsequently found
no significant difference between the level of NS1 IgG in
control patients with past infection and those with chronic
B19 infection (Searle et al., 1998; Venturoli et al., 1998; Jones
et al., 1999). Mapping of B-cell epitopes on NS1 identified
three antigenic regions (amino acids 191–206, 271–286 and
371–386) that were equally reactive with sera from healthy
individuals with past B19 infection and patients who were
infected persistently by B19 (Tolfvenstam et al., 2000). More
recently, by using an E. coli expression system, NS1 IgG
reactivity has been shown to be most prevalent in serum,
following recent infection in pregnant women (61%)
(Hemauer et al., 2000). These findings are supported by the
work of Mitchell et al. (2001), who examined NS1 IgG
reactivity in sera from individuals who were either infected
by B19, had been exposed to B19 but were not infected, were
suffering from a rash illness or chronic arthropathy, or were
healthy controls. NS1 IgG reactivity was predominant in
recently infected specimens and when follow-up samples
from these individuals were analysed, the level of NS1-
specific IgG reactivity had declined. In addition, there was
no evidence of a connection betweenNS1 IgG antibodies and
the development of arthropathy (Mitchell et al., 2001). The
NS1-specific IgG response wanes post-infection as the virus
is cleared from the body; therefore, NS1 IgG reactivity may
have some value as a marker of recent infection, in conjunc-
tion with the detection of IgG against linear epitopes on VP2
(Ennis et al., 2001). This study demonstrated that 69% of
children who had been infected recently by B19 were NS1
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IgG-seropositive (Ennis et al., 2001). Heegaard et al. (2002a)
also observed a seroprevalence of 60% B19 NS1 IgG in
recently infected individuals (,6 weeks post-infection) and
suggested that NS1 IgG detection may significantly improve
immunoassay sensitivity.
It is now clear that B19 IgM and IgG detection is optimal in
immunoassays that utilize VP2 capsids for antibody detec-
tion. Antibody (IgG/M) detection of B19 NS1 protein may
assist in the confirmation of recent B19 infection, when used
in combination with VP2 capsid-based immunoassays.
Erythrovirus V9 antibody detection is also feasible, by using
immunoassays that are based on B19 VP2 capsids.
Cell-mediated immunity
Cell-mediated immunity to B19 has not been studied
extensively; this is due primarily to the fact that the humoral
response was thought to be most important in combatting
B19 infection. Indeed, initial attempts to demonstrate
specific T-cell proliferative responses to B19 were unsuccess-
ful (Kurtzman et al., 1989a) and, for some time, this work
supported the prevailing theory that neutralizing antibody
productionwas themajormechanismof immunity in B19. In
1996, ex vivo B19-specific CD4þ T-cell responses were first
detected againstE. coli-expressedVP1, VP2 andNS1 antigens
(vonPoblotzki et al., 1996). T-cell responses of 16 individuals
were analysed (ten seropositive and six seronegative blood
donors), none of whom had any evidence of acute infection.
The majority (90%) of seropositive donors who were
stimulated ex vivo by VP2 displayed specific T-cell responses,
with 80% displaying VP1-specific responses. There was no
significant difference in T-cell proliferation for NS1 between
seropositive and seronegative individuals. Upon inclusion of
mAbs that were specific for class I and class II HLA, it was
found that HLA class II-specific antibodies inhibited T-cell
proliferation, thus indicating that the effector T-cell popu-
lation of B19 are CD4þ cells. Subsequent peripheral blood
mononuclear cell (PBMC) depletion of either CD4þ or
CD8þ T cells and stimulation of the remaining population
confirmed this observation.
More recently, significant ex vivo T-cell reactivity was ob-
served in PBMCs of recently and remotely infected indivi-
duals by using a B19 candidate vaccine (Franssila et al., 2001)
and also the B19 recombinant proteins, VP1 and VP2
(Corcoran et al., 2000). T cells from recently infected
individuals responded strongly to the B19 capsids, giving a
mean T-cell stimulation index (SI) of 36 (Franssila et al.,
2001). Blood donors with past infections gave comparable
rates of T-cell stimulation. Seronegative individuals had SI
values of about 3.3 and this study also showed that the
responding population of T cells were CD4þ. Although von
Poblotzki et al. (1996) saw no difference in T-cell responses
to NS1 in seronegative and seropositive individuals, signifi-
cant responses to this antigen have been reported in recently
infected individuals and patients who developed chronic
arthropathy following B19 infection (Mitchell et al., 2001).
T-cell responses to NS1 were not seen in healthy individuals
with past B19 infection, except for two individuals who were
also NS1 IgG-seropositive.
Cellular immune response to an epitope of NS1 that is
recognized specifically by CD8þ T cells was investigated
recently by using major histocompatibility complex tetra-
meric complex binding (Tolfvenstam et al., 2001b). The
response of 21 individuals to this epitope was examined in
healthy volunteers and human immunodeficiency virus
(HIV)-1 infected adults and children. Sixteen of the volun-
teers were HLA-matched (HLA B35) and six were mis-
matched. Sixty-three per cent of matched individuals
displayed specific CD8þ T-cell responses. Seventy-two per
cent of matched individuals in the same cohort exhibited
specific T-cell responses by using an interferon ª (IFN-ª)
ELISpot assay. The level of B19-specific CD8þ T cells was
similar among healthy and HIV-infected individuals. The
results presented in this report showed the important cellular
role of cytotoxic T cells in combatting B19 infection
(Tolfvenstam et al., 2001b). B19-specific T-cell responses
may now represent a novel method for confirming past B19
infection.
Recent evidence shows the importance of evaluating T-cell
responses in understanding the nature of B19 infection. Chen
et al. (2001) have identified an AIDS patient with persistent
B19 infection who showed an initial remission of B19
infection. This remission was evident despite the lack of a
specific antibody response, thus indicating a role for cellular
immunity in combatting B19 infection. NS1-reactive lym-
phocytes have been detected in two B19-seronegative in-
dividuals whowere exposed to the virus, indicating a possible
subclinical B19 infection or perhaps a loss of antibodies
against capsid proteins (Mitchell et al., 2001). The impor-
tance of cellular immunity in B19 was further emphasized in
a report by Tolfvenstam et al. (2001b).Here, investigations of
B19-specific CD8þ T-cell responses identified two healthy
adults and two HIV-1-infected patients who were seronega-
tive for B19, with specific T-cell responses against B19 by
either IFN-ª ELISpot or tetramer binding studies, thus
implying the presence of a cellular response in the absence
of a humoral response.
Significant T-cell transcriptional activation has been re-
ported in a patient with acute B19 infection, causing in-
creased levels of interleukin (IL) 1, IL6 and IFN-ª mRNA
(Wagner et al., 1995). A subsequent study that analysed the
sera of patients whowere infected acutely by B19 showed that
although IL1, IL6, IFN-ª and tumour necrosis factor Æ
(TNF-Æ) were secreted during the acute phase of infection,
increased levels of both IFN-ª and TNF-Æ persisted and were
detectable 2–37months later, during a follow-up study (Kerr
et al., 2001). It has also been suggested that cytokine genetic
polymorphisms may, in some way, affect the development of
symptoms during B19 infection. To date, the transforming
growth factor  (TGF) allele has been associated with skin
rash at acute infection and the IFN-ª allele has been
associated with NS1 antibody development (Kerr et al.,
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2003). In a study of recently infected children, it was shown
that although strong T-cell proliferative responses were
evident to both capsid proteins, production of the T helper
(Th1) cytokine IFN-ª, but not of IL2, was impaired when
compared to convalescent adults (Corcoran et al., 2000). In
addition, ex vivo production of IFN-ª and IL2 that was
observed in B19-seropositive pregnant women was lower
than observed previously for healthy, non-pregnant indivi-
duals, suggesting a possible dimunition of the maternal anti-
virus immune response that may subsequently increase the
risk of fetal B19 infection (Corcoran et al., 2003). Expression
of the non-structural protein NS1 causes the production of
increased levels of the inflammatory cytokine IL6 in a
number of cell lines, including hematopoietic cell lines and
human umbilical vein endothelial cells (Moffatt et al., 1996).
IL6 is known to be involved in synovial cell proliferation and,
in addition, high levels of IL6, along with other inflammatory
cytokines, have been found in inflamed joints of patientswith
RA, which would suggest an association between IL6
production and the joint manifestations that are observed
with B19 infection (Bataille et al., 1995). IL6 involvement in
RA is supported by the fact that antibodies against IL6 cause
inhibition of RAmanifestations (Bataille et al., 1995). As well
as increased IL6 production, high levels of IFN-ª, TNF-Æ and
IL8 have been detected in the sera of infants with B19-
associated acute myocarditis (Nigro et al., 2000). IL2
production at the maternal–fetal interface in women who
seroconverted to B19 during pregnancy is thought to
determine the outcome of the pregnancy, with high levels
of IL2 on the fetal side being associated with pregnancies that
result in a poor outcome (Jordan et al., 2001).
B19 vaccine
Ballou et al. (2003) have shown recently that a recombinant
vaccine (MEDI-491; Medimmune) that is comprised of B19
VP1 and VP2 capsid proteins could elicit neutralizing anti-
body titres in volunteer adults (n ¼ 24). Sera from immu-
nized individuals were also shown to be capable of inhibiting
B19 replication in vitro. The efficacy of this formulation in
preventing infection by B19 remains to be established;
nonetheless, it is an encouraging and welcome advance in
the fight against this ubiquitous pathogen.
PCR detection of B19 DNA
Many clinical laboratories now complement B19 antibody
screening with diagnostic PCR and it is well-established that
B19 PCR improves the sensitivity of detection of B19
infection (Skjoldebrand-Sparre et al., 2000; Manaresi et al.,
2002).However, cautionmust be exercizedwith regard to the
deployment of B19 PCR for a number of reasons: (i) the high
viraemia that is associated with B19 infection, along with
resultant amplicon load, may cause PCR false positivity –
particularly when nested PCR is used for B19 detection; (ii)
B19 DNA detection may not always be indicative of an acute
infection; (iii) many PCR assays use in-house primer pairs of
undefined sensitivity of detection; (iv) false negativitymay be
observed with respect to non-B19 strains (e.g. erythrovirus
V9, K71 or A6), due tominor sequence differences (Hokynar
et al., 2002; Nguyen et al., 2002; Servant et al., 2002); and,
finally, (v) many extraction methods are suitable for DNA
purification from serum or plasma only and not from solid
tissue (e.g. placenta or fetal tissue). Notwithstanding these
caveats, some of which are discussed in more detail below,
B19 PCR is an important tool in the technologist’s armoury
for detection of B19 infection.
During acute infection with B19, viral titres can reach1012
genome equivalents ml1 (Prowse et al., 1997). In the
immunocompetent host, virus DNA is detectable for at least
1month post-infection (Erdman et al., 1991). In chronic B19
infection, virus DNA can persist in the host without the
presence of B19 IgM or IgG (Kurtzman et al., 1988;
Frickhofen et al., 1990). However, it has also been shown
that B19 DNA can persist in healthy, immunocompetent
individuals at low levels for long periods (Cassinotti et al.,
1993; Kerr et al., 1995b; Musiani et al., 1995; Cassinotti &
Siegl, 2000). Thus, B19 DNA, detected by qualitative PCR
analysis, is not always indicative of recent infection.
Cassinotti & Siegl (2000) used quantitative PCR to follow
the amount of specific B19 DNA in an immunocompetent
patient, expressed as genome equivalentsml1, from the time
of acute B19 infection until convalescence. A series of
samples was taken over a 1 year period and was analysed by
using a real-time fluorogenic PCR assay. During the viraemic
stage of B19 infection, viral load reached levels of 8.8 3 109
genome equivalents (ml blood)1. At this stage, the patient
was positive for specific IgM and negative for IgG reactivity.
At week 164, viral load had declined to 95 genome equiva-
lents ml1, IgM reactivity was lost and conformational IgG
reactivity was strong. Specimens taken after this time-point
were undetectable for B19 DNA. Thus, whilst the actual
amount of circulating B19 DNA that was present following
B19 infection diminished dramatically after the first few
weeks of infection, it persisted for some time before being
cleared from the host, despite the development of circulating
B19 IgG. This slow rate of B19 DNA clearance from an
immunocompetent host could impact negatively onPCR as a
diagnostic tool in differentiating between recent or chronic
B19 infection in a situation where a qualitative PCR assay of
unspecified sensitivity of detection was employed. However,
with the introduction of the World Health Organization
(WHO) International Standard for Parvovirus B19 DNA
(NIBSC 99/800), PCR assay standardization has become
possible (Saldanha et al., 2002). Using the WHO standard, a
compatible PCR-ELISA that can detect levels as low as
1.6 3 103 IU B19 DNA ml1 was established (Daly et al.,
2002) and, by using real-timePCR technology, a sensitivity of
detection of 15.4 IUml1 (10 Baxter units ml1) (Aberham
et al., 2001) was reached. Mu¨ller et al. (2002) and Thomas
et al. (2003) have also described standardized B19 PCR assay
systems. These standardized methods could be used not only
in a diagnostic setting, but also for rapid screening of plasma
mini-pools and blood products, thereby leading to determi-
nation of the amount of B19 DNA present and improved
product safety.
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PCR may also be used in screening for the newly isolated
erythrovirus V9 (Nguyen et al., 1998, 1999). A nested PCR
assay that is capable of accurately detecting V9 and B19 DNA
simultaneously, comprising a primary round of amplifica-
tion by using a pair of consensus primers and a subsequent
round of amplification by using separate primers for B19 and
V9, has been developed (Heegaard et al., 2001). By using this
PCR assay, clinical samples, including 100 B19 IgM-positive
specimens and untreated plasma pools that represented
100 000 blood donor units from the Danish population,
were screened for both V9 and B19 DNA. None of the
specimens analysed were positive for V9 DNA, whichmay be
due to the facts that this V9 isolate is an emerging virus and
that this erythrovirus may actually be more divergent than
thought previously (Heegaard et al., 2001). Thus, PCR could
be used as a diagnostic tool for the identification of possible
new erythrovirus isolates in cases where patients are negative
for B19 DNA, but have displayed clinical symptoms of B19
infection.
B19 and blood-product safety
B19 can be transmitted through blood transfusions and
plasma-derived products (Prowse et al., 1997; Santagostino
et al., 1997). Screening of blood donations for the presence of
B19 DNA is not routine (Blu¨mel et al., 2002), despite the fact
that this virus is highly resilient and, like the hepatitis A virus,
can withstand denaturation, even at high temperatures
(Santagostino et al., 1994). In fact, B19 can withstand
processes that involve solvent/detergent treatment, lyophili-
zation and temperatures of 100 8C for 30 min and, despite
these harsh virucidal processes, still have the capacity to
contaminate factor VIII and factor IX concentrates
(Santagostino et al., 1997). B19 contamination of such
purified blood products is particularly problematic as, in
the absence of B19 IgG, the infectious potential of B19may be
enhanced (Blu¨mel et al., 2002). The most recent determina-
tion of B19 prevalence is 1 in 625 blood donations (n ¼
16 859; range, 102 to .107 IU B19 DNA ml1) (Thomas
et al., 2003). Previously, B19 had been estimated to be present
in 1 : 16 000 transfusions, based on themean incidence of B19
infection in a non-epidemic period (320 cases per 100 000
population) and the fact that viraemia lasts for about 7 days
(Prowse et al., 1997). During epidemics, the incidence of
viraemia in donations is greatly increased, with levels as high
as 1 : 3790 reported in Ireland (O’Neill & Coyle, 1992) and
1 : 167 in Japan (Yoto et al., 1995).
The infectious level of B19 in blood products has yet to be
established with certainty and is likely to depend on the level
of B19 IgG that is co-present in the product, in addition to
recipient immune status. As part of a phase IV study, a group
of 100 healthy volunteers whowere seronegative for B19were
given 1 unit of plasma that had been solvent/detergent-
treated (Davenport et al., 2000). Of the volunteers who were
screened subsequently for incidences of B19 infection, 18%
had seroconverted over the subsequent 3 months. Three of
the ten batches of plasma that were used in the study were
found retrospectively to contain high levels of B19 DNA
(.107 genome equivalents ml1) and these batches coin-
cided with the plasma that was administered to the volun-
teers who seroconverted. Interestingly, batches with low
amounts of B19 (,104 genome equivalents ml1) did not
cause B19 seroconversion. Upon discovery of these facts, the
company that was involved in manufacturing this plasma
(VITEX, Watertown, MA, USA) voluntarily recalled batches
that were associated with B19 transmission and reviewed
their screening process. Presently, plasma lots that contain
high levels of B19 are eliminated frommanufacturing batches
of plasma. Thus, there is a level of virus, as yet undetermined,
that will not cause B19 infection. Notably, Daly et al. (2002)
undertook a retrospective study of plasma pools (n ¼ 30)
that were similar to those utilized in the study of Davenport
et al. (2000) and found B19 IgG levels in the range of
64.7  17.5 IUml1. Thus, it is possible that this level of B19
IgG may be capable of preventing recipient B19 infection
when transfused with plasma that is contaminated by low
levels of B19 (,104 genome equivalents ml1). Blu¨mel et al.
(2002) have identified two incidences of B19 transmission by
separate lots of clotting factor concentrates and have shown
that B19 levels of 8.6 3 106 genome equivalents ml1
(volume, 180 ml) and 4 3 103 genome equivalents ml1
(volume, 966 ml) were responsible for seroconversion.
B19 seroprevalence is higher among haemophiliacs than the
general population, presumably due to the fact that products
that are derived from pooled plasma are more likely to
contain infectious B19 DNA. This was shown conclusively
when B19 seroprevalence in a haemophiliac population was
compared with that of normal healthy individuals and it was
discovered that haemophilic children who were treated with
virally inactivated clotting factor had an increased level of
B19 seroprevalence (92%) (Eis-Hu¨binger et al., 1996).
Normally, in the general population, a continuous increase
in B19 seroreactivity is observed with age, with a seropreva-
lence for adults over 60 that reaches about 72%. Interest-
ingly, the haemophilic population that was treated pre-1984
with non-inactivated clotting factor concentrates had an
increased seroprevalence of 98% (Williams et al., 1990;
Eis-Hu¨binger et al., 1996).
Despite the fact that B19 infection can be transmitted via
contaminated blood products, there are presently no strict
regulatory prerequisites governing B19 contamination of
pooled plasma or blood products prior to product release.
However, it should be acknowledged that many manufac-
turers now perform B19 PCR on plasmamini-pools, in order
to eliminate high B19 viral load plasma (Aberham et al.,
2001). PCR screening of blood products has been shown to
facilitate removal of 23 B19 PCR-positive donations from a
plasma pool of 6000, resulting in a 10–100-fold decrease in
viral load (Prowse et al., 1997). However, the level of B19
DNA does not necessarily correlate to the rate of infectivity,
as has been demonstrated previously for the canine parvo-
virus; in this case, heat treatment was found to reduce canine
parvovirus infectivity by.100-fold, despite the fact that the
PCR assay titre was unaltered (Hart et al., 1994).
A. Corcoran and S. Doyle
10 Journal of Medical Microbiology 53
Nonetheless, the issue ofwhether high-risk populations, such
as pregnant women, immunocompromised patients and
people with chronic anaemia, should undergo administra-
tion of any B19-containing products while the level of
infectious B19 DNA is unknown and mini-pool screening
is not mandatory must be addressed. The aforementioned
availability of an International Standard preparation of B19
DNA (Saldanha et al., 2002), in addition to a number of
compatible and quantitative B19 PCR detection systems
(Aberham et al., 2001; Daly et al., 2002; Kno¨ll et al., 2002;
Mu¨ller et al., 2002; Thomas et al., 2003), should alleviate
problems caused by ambiguity between results from labora-
tories that use various methods of measuring and expressing
B19 DNA levels and help to determine the infectious dose
for B19.
It is highly significant that, in the Netherlands, a recommen-
dation has been made that individual donor screening for
B19 IgG to identify individual donors with continually high
antibody levels (at t ¼ 0 and 6 months) should be initiated
(Health Council for the Netherlands, 2002; Groeneveld &
van der Noordaa, 2003). Selected individuals who maintain
high B19 IgG levels will subsequently form a panel of plasma
or blood-product donors for high-risk recipients, such as
immunocompromised individuals, thereby minimizing the
risk of B19 transmission from acutely infected, although
asymptomatic, donors. It is our view that the introduction of
such a screening algorithm sets the standard for blood-
product safety in the future, specifically with respect to
minimizing the risk of B19 transmission.
Assays that are based on exploitation of the P antigen
receptor of B19, known as receptor-mediated haemaggluti-
nation, have been proposed as a cheap way to screen plasma
and to apparently detect whole virus; however, assay sensi-
tivity is quite low, especially when compared to that of PCR
(Cohen & Bates, 1995; Sato et al., 1995; Wakamatsu et al.,
1999). A novel immunoassay that is capable of detecting 1–
2 3 106 genome equivalents of B19 antigen (whole virus), in
the presence or absence of B19 IgG/M, is currently under
development (O’Keeffe et al., 2003) and should find an
application in either mini-pool or diagnostic screening, as an
adjunct to PCR screening.
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Fig. 2. Schematic depiction of T- and B-cell response to parvovirus B19 infection. Upon B19 infection, B cells divide to produce
plasma cells and memory cells. Plasma cells secrete IgM antibodies that are specific for both conformational (N) and linear (D)
epitopes of B19, which are detectable approximately 7 days post-infection. B19-specific IgG is detectable about 15 days post-
infection and is directed initially against both linear and conformational epitopes of the capsid proteins (VP1 and VP2) and, to a lesser
extent, against NS1, but declines against linear epitopes of the proteins in a time-dependent manner. Infection by B19 most likely
confers lifelong protection on the host, due to the development of memory B cells that are specific for conformational regions of the
B19 capsid and also linear regions of the VP1 protein (Corcoran et al., 2004). Antigen-presenting cells (APC) process the virus and
display B19 peptides on their surface to Th cells. These Th cells then secrete cytokines that play a role in mediating anti-virus immunity
and may also be associated with pathogenesis of B19 infection (e.g. IL6 is associated with RA).
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